The estimated Net Worth of Kevin Schultz is at least $37 mil dollars as of 12 December 2013. Kevin Schultz owns over 4,000 units of Kindred Biosciences Inc stock worth over $37,000 and over the last 11 years Kevin sold KIN stock worth over $0.
Kevin has made over 1 trades of the Kindred Biosciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Kevin bought 4,000 units of KIN stock worth $28,000 on 12 December 2013.
The largest trade Kevin's ever made was buying 4,000 units of Kindred Biosciences Inc stock on 12 December 2013 worth over $28,000. On average, Kevin trades about 2,000 units every 0 days since 2013. As of 12 December 2013 Kevin still owns at least 4,000 units of Kindred Biosciences Inc stock.
You can see the complete history of Kevin Schultz stock trades at the bottom of the page.
Kevin's mailing address filed with the SEC is C/O KINDRED BIOSCIENCES, INC., 1499 BAYSHORE HIGHWAY, SUITE 226, BURLINGAME, CA, 94010.
Over the last 11 years, insiders at Kindred Biosciences Inc have traded over $10,542,886 worth of Kindred Biosciences Inc stock and bought 50,952,388 units worth $461,948,778 . The most active insiders traders include Animal Health Inc Elanco, West Asset Management Llc Park, eErnest Mario. On average, Kindred Biosciences Inc executives and independent directors trade stock every 34 days with the average trade being worth of $5,949,674. The most recent stock trade was executed by Animal Health Inc Elanco on 27 August 2021, trading 45,508,938 units of KIN stock currently worth $420,957,677.
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
Kindred Biosciences Inc executives and other stock owners filed with the SEC include: